Contribute Try STAT+ Today

During a recent five-year period, Medicare spending on hundreds of medicines to treat various neurologic conditions, such as epilepsy and multiple sclerosis, rose 50%, but the number of claims increased only 8%, according to a new study.

Consequently, Medicare spent $4 billion in 2013 but doled out $6 billion by 2017 for these treatments. In addition, neurology medicines, mostly those used to combat multiple sclerosis, accounted for more than 50% of total Medicare payments, despite representing just 4% of all claims filed. The study also found that spending for these drugs rose 47%, from $3,337 per claim to $4,902.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Yawn. Glowing press coverage for another meaningless list price study.

    Contrary to Ed’s statement above, this study did *not* reflect post-purchase rebates from pharmacies and manufacturers, a.k.a., DIR. Instead, it relied on “negotiated prices,” which reflect the rates than Part D plans paid to pharmacies. These negotiated rates approximate list prices for brand-name drugs. (BTW, the article neglects to acknowledge this limitation.)

    Consequently, this shoddy study adds nothing to the debate, since many of these drugs had large and growing rebates during this period.

Comments are closed.